Top-line data from Janssen’s eagerly-awaited clinical trial into Zytiga (abiraterone acetate) in combination with the standard of care for advanced prostate cancer have been released.
The data show that the relative risk of death was lowered by 37%. The three-year survival rate was 76% with standard therapy alone, but 83% with standard therapy plus Zytiga.
Severe side effects were more common in the test group, occurring in 41% of patients, compared to 29% of patients in the standard therapy group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze